Company insight T cells leading the way
While Covid-19 testing and vaccine monitoring is important in reducing disease transmission and for clinical management, antibody tests have limitations, particularly with new variants like Omicron. Here, Dr Anthony Allen of Oxford Immunotec describes how T cell tests help provide a fuller picture of an individual’s immune response and could be a significant addition to the Covid-19 test panel, less affected by the changing landscape of variants of concern.
micron, a SARS-CoV-2 variant that spread rapidly around the world in November 2021, caused widespread concern due to its high transmissibility and ability to infect those previously exposed or immunised. The rapid spread led to reported Covid- 19 cases in the UK increasing from just over 305,000 in the week the first case of Omicron was described (24 November), to over 1.1 million cases by the beginning of January. Concerns immediately arose about our body’s immune response to the new variant and whether neutralising antibodies elicited by vaccines, or acquired by previous infection, could protect us from Omicron.
O
Omicron evades antibody response Increased immunity in individuals, from natural infection or vaccination, could serve to drive selection pressure on the virus, either to increase transmissibility or to allow evasion of the antibody response. The Omicron variant has significantly more mutations than the previous variants with 34 mutations in the S protein alone, and research has shown that immune evasion is an integral driver in its development, with affinity- enhancing changes being sacrificed in favour of immune-evading alterations. Omicron therefore, appears to be both more transmissible and able to, at least partially, evade the immune response.
T cells come to the rescue Previous research on SARS-CoV-2 virus polymorphisms revealed an antibody evasion mechanism that led to infection; however, this mechanism does not seem to evade the T cell response. This being the case, the understanding is that new variants, like Omicron and those that come after, may have high susceptibility to T cell responses.
Practical Patient Care /
www.practical-patient-care.com
Oxford Immunotec’s
T-SPOT.COVID kit that has demonstrated accurate diagnosis of immune response
According to a study performed at Karolinska Institutet, the Omicron variant can partially bypass the antibody response elicited to prior SARS-CoV-2 variants via vaccination or infection. However, T cells still recognise Omicron. Both those with previous infection and those with vaccination had memory T cells that could recognise the Omicron S protein with the vaccinated group responding the best.
There is reason to believe that overall protection from SARS-CoV-2 vaccines might be jeopardised when paired with the predicted loss of neutralisation from antibodies. However, vaccination effectiveness against symptomatic illness has typically been sustained and is possibly associated with the T cell response rather than neutralising antibodies.
Usefulness of T cell testing Studies using T cells have shown that patients with B cell depletion did not produce antibodies against SARS-CoV-2
vaccination, but did generate SARS-CoV-2 specific T cells. A similar phenomenon was noticed in individuals with multiple sclerosis post-vaccination. T cell testing has also highlighted the significantly impaired T cell and antibody responses to Covid-19 vaccines in haematopoietic stem cell transplant recipients, prompting clinicians to provide extra care for these patients throughout the pandemic. During the beginning of the Covid-19 pandemic, the focus on antibodies led to the rapid development of serology tests. However, as scientists begin to deal with the unfortunate generation of new variants of concern, relying on this method alone may be less effective. Use of approved T cell testing in vaccination and long-term surveillance programmes may help to fully understand immunological correlates of SARS-CoV-2 protection. ●
References are available on request.
www.oxfordimmunotec.com 19
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63
